Platinum Drugs for Lung Cancer Treatment
Author Information
Author(s): Cosaert J, Quoix E
Primary Institution: AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire, UK
Hypothesis
The review investigates the effectiveness of platinum-based chemotherapy in treating non-small-cell lung cancer (NSCLC).
Conclusion
Platinum-based chemotherapy is considered standard treatment for advanced NSCLC, despite issues with toxicity and resistance.
Supporting Evidence
- Platinum-based chemotherapy has been shown to prolong survival in patients with advanced NSCLC.
- Cisplatin and carboplatin are the most commonly used platinum drugs.
- Combination therapies involving platinum drugs have improved response rates compared to monotherapy.
- New platinum agents are being developed to overcome resistance and reduce toxicity.
Takeaway
Doctors use special medicines called platinum drugs to help people with a type of lung cancer called non-small-cell lung cancer, but these medicines can sometimes make people feel sick.
Methodology
The review summarizes findings from randomized clinical studies and meta-analyses regarding the use of platinum-based chemotherapy.
Potential Biases
Potential bias in the selection of studies included in the review.
Limitations
The review does not provide new clinical trial data but summarizes existing literature.
Participant Demographics
The review discusses findings from studies involving patients with advanced non-small-cell lung cancer.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website